Asthma is a common and potentially serious condition affecting 300 million people worldwide. For many years, we have relied on a one-size-fits-all approach to its management, using corticosteroids and bronchodilators for all symptomatic patients. However, with more recent advances, it has become clear that asthma is a heterogeneous condition with multiple different underlying pathways. Understanding the different subtypes will be a key to giving us the ability to intervene in a targeted way to personalize care for patients with asthma.

中文翻译：

---

针对哮喘的靶向生物疗法。

哮喘是一种常见且潜在的严重疾病，全世界有3亿人受到影响。多年来，我们一直采用一种一刀切的管理方法，对所有有症状的患者使用皮质类固醇和支气管扩张剂。但是，随着最近的进展，很明显哮喘是一种异质性疾病，具有多种不同的潜在途径。了解不同的亚型将是使我们能够有针对性地进行干预以个性化哮喘患者护理的关键。